Alterity Therap Limited (ATH) TRADING HALT SUSPENDED

20mins delayed

Movement

1 Year Return


Alterity Therap Limited Chart

Share price
Last
Change
Volume
Turnover
Market Cap $22.59 million
Today's Movement
Prev. Close
Open
Day Range -
VWAP
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover
(delayed)

ATH Statistics

21 November

1,410 / 2,299

ASX Size Rank

1yr Return

vs Sector (1yr)

-78.23%

vs ASX 200 (1yr)

-53.26%

$22.59 million

Market Cap

Share Issue

868.8 million

All Ords (%)

N/A

Short Sold

0%

Current Fundamentals

21 November

N/A

PE Ratio

EPS ($)

-0.02

Earnings Yield

-76.92%

NTA ($)

0.02

N/A

Dividend Yield

DPS ($)

-

Gross Div. Yield

-

Gross DPS ($)

-

Company Overview

Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is an Australian biotechnology company with a focus on the development of pharmaceutical products designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses Potential applications for ATH's MPAC (Metal-Protein Attenuating Compound) technology including Alzheimer's, Parkinson's and Huntington's diseases and brain cancer.

Former Names
Prana Biotechnology Ltd (PBT), 11/04/2019

Alterity Therap Limited Logo

Corporate Details

Head Office: Melbourne
Managing Director: Geoffrey Kempler
GICS Sub-Industry: Biotechnology
Date Listed: 28 Mar 2000
Registry: -
Similar Companies: CSL / SRX / MSB / CUV / VLA

Upcoming Calendar

27 Feb 2020 Report (Interim)
28 Aug 2020 Report (Prelim)
28 Aug 2020 Report (Annual)
31 Aug 2020 Report (Annual)

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.

Announcements

Date Heading Pages File Size Time

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

ATH is not covered by a major broker.

Directors & Management

About the Data


Name Title Since Bio
Mr David Sinclair Non-Executive Director Apr 2019
Mr Geoffrey Paul Kempler Executive Director, Chief Executive Officer, Executive Chairman Nov 1997
Mr Brian Derek Meltzer Non-Executive Director Dec 1999
Mr Peter Marks Non-Executive Director Jul 2005
Mr Lawrence Gozlan Non-Executive Director Aug 2011
Mr Tristan Edwards Non-Executive Director Apr 2019
Ms. Kathryn Andrews Chief Financial Officer N/A
Dr. David Stamler Chief Medical Officer and Senior Vice President Clinical Development N/A
Phillip Hains Company Secretary N/A

Director Transactions

About the Data

ATH directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
16/11/18 Ira Shoulson Issued 1,250,000 $0.044 $55,000 Issue of options.

Shareholder Distribution

About the Data

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over Total Shareholders
No. of Shareholders 506 941 439 858 217 2,961

Top 20 Shareholders

About the Data

Name Shares Capital
HSBC Custody Nominees (Australia) Limited 413,392,841 47.58%
Life Biosciences Llc 269,905,533 31.07%
Jagen Pty Ltd 15,567,983 1.79%
Baywick Proprietary Limited 14,165,000 1.63%
Marquette Holdings Pty Limited 7,692,308 0.89%
J P Morgan Nominees Australia Pty Limited 6,143,499 0.71%
Donatello Nizzi 4,678,362 0.54%
Ms Jia Lu 4,309,879 0.50%
Schwa Pty Ltd 4,000,000 0.46%
Mr James V Babcock 3,980,263 0.46%
The Entrust Group Inc 3,598,740 0.41%
Citos Super Pty Ltd 3,085,499 0.36%
Nrb Developments Pty Ltd 2,970,000 0.34%
Ms Chao Lei 2,520,422 0.29%
Hsbc Custody Nominees (Australia) Limited A/C 2 2,421,246 0.28%
Stony Rises Pty Ltd 2,035,000 0.23%
Mr David John Southon 2,000,000 0.23%
Moubray Pty Ltd A/C> 2,000,000 0.23%
Robert & Ardis James Foundation/C 1,826,024 0.21%
Mrs Kate Elizabeth Schroeter 1,724,993 0.20%
All other shareholders 11.59 %


The Top 20 Shareholders of ATH hold 88.41% of shares on issue.

ATH Share Price History

Date Close Change % Change Open High Low Volume Turnover

ATH Historical Data

Download up to 20 years of share price history.


Year Closing Price (30 June) Last Trade

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.

Incorporated: in VIC on 11/11/1997 as Prana Corporation Pty Ltd. Incorporation status changed to "Limited" on 26/11/1999. Name changed to Prana Biotechnology Limited on 05/01/2000.

Level 3, 460 Bourke St
Melbourne VIC 3000


All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.